Previous 10 | Next 10 |
HOUSTON , Oct. 10, 2019 /PRNewswire/ -- Soliton, Inc. (NASDAQ: SOLY), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into defi...
October 8, 2019 Palm Beach, FL – October 8, 2019 – Medical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and lifestyle diseases – trends that expand healthcare spending. W...
HOUSTON , Oct. 8, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced ...
HOUSTON , Oct. 3, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today annou...
HOUSTON , Oct. 1, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today an...
HOUSTON , Sept. 24, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ...
HOUSTON , Sept. 19, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ...
HOUSTON , Sept. 17, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ann...
HOUSTON , Sept. 10, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today ann...
HOUSTON , Sept. 9, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced...
News, Short Squeeze, Breakout and More Instantly...
Allergan Aesthetics Completes Acquisition of Soliton -- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite -- PR Newswire IRVINE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie comp...
On a gloomy day for the stock market, healthcare aesthetics specialist Soliton (NASDAQ: SOLY) was a luminous bright spot on Tuesday. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close. ...
Soliton Inc. (NASDAQ:SOLY) traded today at a new 52-week high of $22.60. So far today approximately 147,000 shares have been exchanged, as compared to an average 30-day volume of 103,000 shares. Based on a current price of $22.53, Soliton Inc. is currently 19.0% above its average consens...